Healthcare Global Enterprises Limited

rs,

Mumbai - 400051, Maharashtra, India BSE Limited, Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India Dear Sir/Madam, Subject : Stock Code : BSE –

rs1

Largest Pan-India Oncology Hospital Chain 2 22 4* 6 Center of Excellence (CoE) Cancer Care Centers1 Multi-specialty hospitals Day care centers Jaipur Ahmedabad Indore Ranchi Rajkot Bhavnagar B

55%

ngole Suchirayu Hubli Shimoga Vijaywada Kenya Bangalore LARGEST GEOGRAPHICAL REACH… 10 19 ~55% Number of states covered5 Number of cities covered5 Addressable market3 (population) 25 16/1

14%

G ONCOLOGY MARKET IN INDIA INDIA IS A SIGNIFICANTLY UNDER-COVERED CANCER INDUSTRY INRbn CAGR 13-14% Population coverage by cancer registries1 CAGR 12% 3% 263 3% 1% 151 1% 3% 97% 89% 2019

12%

NDER-COVERED CANCER INDUSTRY INRbn CAGR 13-14% Population coverage by cancer registries1 CAGR 12% 3% 263 3% 1% 151 1% 3% 97% 89% 2019 Population growth Cancer incidences Relapse driven

3%

COVERED CANCER INDUSTRY INRbn CAGR 13-14% Population coverage by cancer registries1 CAGR 12% 3% 263 3% 1% 151 1% 3% 97% 89% 2019 Population growth Cancer incidences Relapse driven Af

1%

R INDUSTRY INRbn CAGR 13-14% Population coverage by cancer registries1 CAGR 12% 3% 263 3% 1% 151 1% 3% 97% 89% 2019 Population growth Cancer incidences Relapse driven Affordability R

97%

CAGR 13-14% Population coverage by cancer registries1 CAGR 12% 3% 263 3% 1% 151 1% 3% 97% 89% 2019 Population growth Cancer incidences Relapse driven Affordability Realization 2024

89%

R 13-14% Population coverage by cancer registries1 CAGR 12% 3% 263 3% 1% 151 1% 3% 97% 89% 2019 Population growth Cancer incidences Relapse driven Affordability Realization 2024 2030E

41%

2019 Population growth Cancer incidences Relapse driven Affordability Realization 2024 2030E 41% 10% 1 in every 9 people in India to potentially suffer from cancer by 2025 Sources: Globacan 201

10%

Population growth Cancer incidences Relapse driven Affordability Realization 2024 2030E 41% 10% 1 in every 9 people in India to potentially suffer from cancer by 2025 Sources: Globacan 2018, IC

81%

key problems LOW EARLY-STAGE DIAGNOSIS IN INDIA… … LEADING TO HIGH MORTALITY TO INCIDENCE RATIO 81% 71% 73% 29% 31% 30% 19% 8% 31% 26% 25% 15% 51% 52% 56% 17% 22% 28% 33% 23% 88%

“Although the Company believes that such forward‐looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met.”

“c o m 19 Kolkata: EBITDA breakeven already demonstrated, paving the way for further profitable ramp up Specific factors that delayed ramp up of the Kolkata center Focused action plan to implement specific initiatives Turnaround already visible through leading indicators of patient flow metrics ?”

“No 1 2 Particulars Capex incurred till 31st December 2024 Total Planned Capex Expected date of Operations North Bangalore Whitefield (Extension of Bangalore - COE) 136 52 900 290 Q3 FY26 Q1 FY26 1.”

“c o m Q3 & 9M FY25 Consolidated Profit & Loss Account Profit and Loss (in Rs.”

Subject

1

Footprint optimisation

1

Subject

Stock Code : BSE – 539787, NSE – HCG Investor Presentation We wish to inform you that the Board of Directors of the Company, at their meeting held on February 14, 2025, inter alia, has approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2024 (“Financial Results”). In this respect, we enclose herewith the Presentation on the Financial Results of the Company for the quarter and nine months ended December 31, 2024. Request you to take this on record. Thanking you, For HealthCare Global Enterprises Limited Sunu Manuel Company Secretary & Compliance Officer Encl: a/a. HealthCare Global Enterprises Limited HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027. 080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489 HEALTHCARE GLOBAL ENTERPRISES LIMITED I NV ESTOR P RESENTATI ON February 2025 SAFE HARBOR This presentation and its contents are confidential

Footprint optimisation

Exit from Kochi; tactical delay in Delhi centre Rationalized capex allocation to focus on single-specialty (Discarding MS expansion in Jaipur) ✓ ✓ ✓ Meaningful cost savings KR + DR Nagpur Pricing optimization HCC Jaipur 7 Functional Heads Consolidation of minority interest in certain hospitals (Suchirayu, Nagpur) Dynamic workforce management Cuttack Borivali Sources: Company information www.hcgoncology.com www . h c g o n c o l o g y. c o m 15 Driving higher growth in market leading centers Centre of Excellence Upcoming Centre of Excellence Premier non-metro center KR HCC Cuttack Revenue Key Interventions Source: Company information FY18 FY20 FY24 FY18 FY20 FY24 FY18 FY20 FY24 ⚫ Engaged seasoned Regional Head ⚫ Strong Doctor Partner alignment ⚫ Strong Doctor Partner alignment ⚫ Strengthened clinical team and bandwidth across modalities driving more complex case mix ⚫ Increased sales and marketing budget and enhanced marketing efficiencies across B2B and B2C channels ⚫ Driving Internati